Slide Show: Kidney Cancer

Slideshow

This kidney cancer slide show features images of chromophobe, papillary, and clear-cell renal cell carcinomas; as well as sarcomatoid, transitional cell, and small-cell carcinomas of the kidney.

Recent Videos
7 experts are featured in this series.
The development of multimodal biomarkers may help predict response to immunotherapy among patients with melanoma and other malignancies.
7 experts are featured in this series.
7 experts are featured in this series.
2 KOLs are featured in this series.
Related Content
The efficacy of TTFields was greater among patients who received immune checkpoint inhibition for the treatment of brain metastatic NSCLC.

TTFields After SRS Prolongs Intracranial Response in Brain Metastatic NSCLC

Roman Fabbricatore
September 30th 2025
Article

The efficacy of TTFields was greater among patients who received immune checkpoint inhibition for the treatment of brain metastatic NSCLC.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

While metastasis-directed therapy has shown it may be a tool for prolonging PFS in other research, progression does still occur in most patients.

Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate Cancer

Tim Cortese
September 29th 2025
Article

The addition of 177Lu-PNT2002 did not significantly increase toxicity in patients with oligorecurrent prostate cancer who received SBRT.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

The 2-year rates for disease-free survival in the radiation and observation arms, respectively, were 71.6% vs 58.7%.

Adjuvant Radiation Therapy Improves Local Survival in High-Risk MIBC

Roman Fabbricatore
September 29th 2025
Article

No toxicity-related discontinuations were seen with adjuvant radiotherapy among patients with muscle-invasive bladder cancer.

Apalutamide plus stereotactic radiotherapy may be effective for certain patients with recurrent prostate cancer following radical prostatectomy.

PAM50 Biomarker May Predict Apalutamide Efficacy in Prostate Cancer

Russ Conroy
September 29th 2025
Article

Apalutamide plus stereotactic radiotherapy may be effective for certain patients with recurrent prostate cancer following radical prostatectomy.